Alemtuzumab
- Atc Codes:L01XC04
- CAS Codes:216503-57-0
- PHARMGKB ID:216503-57-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Mabcampath; Belgium: Mabcampath; Bulgaria: Mabcampath; Cyprus: Mabcampath; Czech Republic: Mabcampath; Denmark: Mabcampath; Estonia: Mabcampath; Finland: Mabcampath; France: Mabcampath; Germany: Mabcampath; Greece: Mabcampath; Hungary: Mabcampath; Ireland: Mabcampath; Italy: Mabcampath; Latvia: Mabcampath; Lithuania: Mabcampath; Malta: Mabcampath; Netherlands: Mabcampath; Poland: Mabcampath; Portugal: Mabcampath; Romania: Mabcampath; Slovakia: Mabcampath; Slovenia: Mabcampath; Spain: Mabcampath; Sweden: Mabcampath; UK: Mabcampath.
North America
Canada: Mabcampath; USA: Campath.
Latin America
Mexico: Mabcampath.
Drug combinations
Chemistry
Alemtuzumab: Mw: approx. 150000.01. (1) Immunoglobulin G~1~, anti-(human CD52 (antigen))(human-rat monoclonal CAMPATH-1H, γ~1~-chain), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer; (2) Immunoglobulin G~1~ (human-rat monoclonal CAMPATH-1H γ~1~-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer. CAS-216503-57-0 (1999).
Pharmacologic Category
Other Antineoplastic Agents; Monoclonal Antibodies. (ATC-Code: L01XC04).
Mechanism of action
Binds to CD52, a nonmodulating antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes, producing an antibody-dependent lysis of leukemic cells.
Therapeutic use
B-cell chronic lymphocytic leukemia.
Pregnancy and lactiation implications
May cross the barrier and cause fetal B- and T-lymphocyte depletion. Use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. Breast-feeding should be discontinued during treatment and for at least 3 months following the last dose.
Unlabeled use
Treatment of refractory T-cell prolymphocytic leukemia, rheumatoid arthritis, graft vs host disease, multiple myeloma. Preconditioning regimen for stem-cell transplantation and renal and liver transplantation. Post-transplant rejection (renal). Treatment of autoimmune cytopenia.
Contraindications
Warnings and precautions
Hazardous agent. Risk of hematologic toxicity (prolonged myelosuppression, autoimmune anemia, and autoimmune thrombocytopenia have occurred). Infections (bacterial, viral, fungal, and protozoan) have occurred. Infusion-related reactions may occur. Men of reproductive potential or women of childbearing potential should use effective contraceptive methods during treatment and for a minimum of 6 months following therapy. Patients should not be immunized with live, viral vaccines during or recently after treatment.